WASHINGTON, D.C. – The Internal Revenue Service (IRS) needs to update and expand the list of services and treatments for chronic diseases covered under an employer-sponsored high-deductible health plan (HDHP), write Ways and Means Committee Chairman Jason Smith (MO-08), Health Subcommittee Chairman Vern Buchanan (FL-16), and Ways and Means Committee Member Representative Jimmy Panetta (CA-19) in a letter today to Acting IRS Commissioner Gary A. Shapley, Jr. Under IRS Notice 2019-45, established during the first Trump Administration, HDHPs can provide coverage for high-value chronic disease management services without requiring individuals to first meet a deductible. Such services and treatments currently include items like beta-blockers for patients with congestive heart failure, blood pressure monitors for patients with hypertension, and glucometers for patients with diabetes, among others.
In their letter to Acting Commissioner Shapley, Chairman Smith, Health Subcommittee Chairman Buchanan, and Ways and Means Committee Member Representative Panetta detail the prevalence of chronic disease and the extent to which treatments drive a substantial amount of the nation’s health care spending – underscoring the need for expanding coverage to additional treatments:
“Six in ten Americans live with at least one chronic disease, and nearly 90 percent of our nation’s $4.5 trillion in annual health care spending goes toward treating patients with chronic and mental health conditions. Chronic diseases are among the ten leading causes of death in the United States. Americans continue to face rising health care costs due to the high prevalence of chronic disease, with out-of-pocket health care costs alone increasing by over 7 percent in 2024. These cost increases pose an acute challenge for the more than half of American workers enrolled in a high-deductible health plan (HDHP)…
“We ask that you use your authority to make updating Notice 2019-45 a top priority of the agency to expand the list of allowed chronic disease management services. An expansion of this policy would have a significant impact on millions of Americans and will mark a powerful step toward ending the chronic disease epidemic.”
This request follows Ways & Means Committee activity examining the chronic disease epidemic in the United States – including hearings focused on the need for greater chronic disease prevention and treatments, ways to empower patients and families with options and incentives to promote healthier living, and the importance of early detection. Additionally, last month, the U.S. House of Representatives approved H.R. 919, the Chronic Disease Flexible Coverage Act, which would codify in law the 2019 Trump Administration guidance and improve the health of millions of Americans living with chronic disease.
Read the full letter here.
READ: House Approves Legislation Expanding Access to Chronic Disease Treatments
READ: Four Key Moments: Hearing on Chronic Disease Prevention and Treatment